(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 31 December 2003 (31.12.2003)

PCT

(10) International Publication Number WO 2004/001009 A3

(51) International Patent Classification⁷: C12N 15/19, C07K 14/525

A61K 38/19,

(21) International Application Number:

PCT/US2003/019750

(22) International Filing Date: 23 June 2003 (23.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/391,050 24 June 2002 (24.06.2002) US

(71) Applicant (for all designated States except US): GENEN-TECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080 (US).

(72) Inventors; and

Inventors/Applicants (for US only): HYMOWITZ, (75)Sarah [US/US]; 1501 Beach #301, San Francisco, CA 94123 (US). KELLEY, Robert, F. [US/US]; 1029 San Felipe Avenue, San Bruno, CA 94066 (US). LINDSTROM, Stephanie, Ho [US/US]; 20 Queen Anne Court, Millbrae, CA 94030 (US).

(74) Agent: MARSCHANG, Diane, L.; Genentech, Inc., MS 49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 28 October 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(54) Title: APO-2 LIGAND/TRAIL VARIANTS AND USES THEREOF

(57) Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/19750

A. CLASSIFICATION OF SUBJECT MATTER IDC/(7) A61V 38/10: G12N 15/10: C07V 14/525				
IPC(7) US CL	: A61K 38/19; C12N 15/19; C07K 14/525 : 424/85.1; 514/2; 435/69.5, 172.3, 252.3, 320	11: 536:23.1. 23.5. 24.31		
	International Patent Classification (IPC) or to both			
B. FIEL	DS SEARCHED			
	cumentation searched (classification system followed 24/85.1; 514/2; 435/69.5, 172.3, 252.3, 320.1; 536			
Documentation	on searched other than minimum documentation to the	e extent that such documents are included	l in the fields searched	
	ta base consulted during the international search (national source) ontinuation Sheet	me of data base and, where practicable, s	earch terms used)	
C. DOC	UMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.	
Y	WO 01/00832 (GENENTECH, INC.) 04 January 2		1-30 and 32	
A	US 6,284,236 B1 (WILEY et al.) 04 September 2001 (04.09.2001)		1-30 and 32	
E, X	WO 03/029420 A2 (GENENTECH, INC.) 10 April 2003 (10.04.2003), Table 1		1-30 and 32	
Further	documents are listed in the continuation of Box C.	See patent family annex.		
"A" document	decial categories of cited documents: defining the general state of the art which is not considered to icular relevance	"T" later document published after the int priority date and not in conflict with understand the principle or theory un	the application but cited to	
_	plication or patent published on or after the international filing	"X" document of particular relevance; the considered novel or cannot be consided step when the document is taken alon	ered to involve an inventive	
"L" document to establis (as specifi	which may throw doubts on priority claim(s) or which is cited the publication date of another citation or other special reason ied)	"Y" document of particular relevance; the considered to involve an inventive ste combined with one or more other suc combination being obvious to a perso	p when the document is n documents, such	
"O" document	referring to an oral disclosure, use, exhibition or other means	•		
	published prior to the international filing date but later than the	"&" document member of the same patent	ramily	
Date of the ac	ctual completion of the international search	Date of mailing of the international sear	ch report	
22 July 2004		-1 HUU ZUUA		
Mail Com P.O. Alex	illing address of the ISA/US Stop PCT, Attn: ISA/US missioner for Patents Box 1450 andria, Virginia 22313-1450 . (703) 305-3230	Rachel B. Kapust Telephone No. (703) 308-0196	allens for	
	. (703) 303-3230 ./210 (second sheet) (July 1998)			
······································	u 210 (cooding direct) (dury 1990)		1 /	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/19750

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)			
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
1. Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
2. Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
3. Claim Nos.: 31 and 33-38 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)			
This International Searching Authority found multiple inventions in this international application, as follows:			
 As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 			
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.			

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

•		
	PCT/US0	
INTERNATIONAL SEARCH REPORT	,	
<u> </u>		
	1	
i		
Continuation of B. FIELDS SEARCHED Item 3:		
DAGE AND DE CANADA GENERAL PROPERTY OF THE CONTROL		
EAST, MEDLINE, CAPLUS, SCISEARCH, BIOSIS, USPATFULL, PCTF	ULL	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	OLL sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	ULL sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	outensist, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	outensism, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	outensism, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	ULL sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	ULL sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	outensist, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	ULL sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	ULL sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	ULL sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	outent, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	ull sm, mutant, mutation, substitution	į
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	outenser, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	out the second substitution substitution substitution	i
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	ULL sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	ull sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	SM, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	ull sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	SM, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	SM, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	SM, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	Sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	
search terms: TNFS10, TRAIL, APO2L, APO2 ligand, variant, polymorphi	sm, mutant, mutation, substitution	

Form PCT/ISA/210 (second sheet) (July 1998)